Прогностические критерии клинического течения и диагностика медуллярного рака щитовидной железы

Проведено ретроспективно-проспективное клиническое аналитическое исследование 137 пациентов с медулляр- ным раком щитовидной железы (МРЩЖ). Выявлена крайне низкая 35%-ная чувствительность тонкоигольной аспи- рационной биопсии и высокая чувствительность исследования уровня базального кальцитонина в диагностике МРЩЖ. Представлены результаты изучения спектра герминальных и спорадических мутаций генов RET и RAS на российской популяции, доказано влияние вида мутации на агрессивность течения МРЩЖ.

медуллярный рак щитовидной железы, синдром множественных эндокринных неоплазий 2 типа, кальцитонин, раковоэмбриональный антиген, RET-протоонкоген, тонкоигольная аспирационная биопсия

1. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Internal Med. 2003;253(6):616-626.

2. Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a` calcitonine. Clin Endocrinol. 1998;48:265-273.

3. Hahm JR, Lee MS, Min YK et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid. 2001;11:73-80.

4. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004; 89:163-168.

5. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1-48.

6. Kebebew E, Kikuchi S, Duh QY, Clark OH. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg. 2000;135:895-901.

7. Agrawal N, Jiao Y, Sausen M et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98(2):364-369.

8. Ciampi R, Mian C, Fugazzola L et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid. 2013;23(1):50-57.

9. Stepanas AV, Samaan NA, Hill CS, Hickey RC. Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer. 1979;43:825-837.

10. Fugazzola L, Pinchera A, Luchetti F et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers. 1994;9:21-24.

11. Sobin LH, Gospodarowicz MK, Wittekind Ch. TNM Classification of malignant Tumors, 7th ed. Wiley-Blackwell Oxford. 2009.

12. Реброва ОЮ. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа Сфера, 2002. 312 с.

13. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638- 2648.

14. Pelizzo MR, Boschin IM, Bernante P et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. 2007;33:493-497.

15. Franc S, Niccoli-Sire P, Cohen R et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol. 2001;55:403-409.

16. Chambon G, Alovisetti C, Idoux-Louche C et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: Results from 2733 consecutive patients. J Clin Endocrinol Metab. 2011;96(1):75-81.

17. Beressi N, Campos JM, Beressi JP. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid. 1998;8:1039-1044.

18. Hamy A, Pessaux P, Miralli e E. Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. Eur J Surg Oncol. 2005;31:774-777.

19. Kaserer K, Scheuba C, Neuhold N. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of consecutive patients. Am J Surg Pathol. 2001;25:1245-1251.

20. Ahmed SR, Ball DW. Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. J Clin Endocrinol Metab. 2011;96:1237-1245.

21. Кондратьева ТТ. Возможности цитологического метода в диагностике нетипичных вариантов рака щитовидной железы. Рак щитовидной железы. ESO RED SQUARE SEMINAR. М.: 2004:2931.

22. Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol. 2000;22:351-358.

23. Paszko Z, Sromek M, Czetwertynska M et al. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindreds from Central Poland. Cancer Invest. 2007;25:742-749.

24. Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid. 2001;11:637-645.

25. Frank-Raue K, Hoppner W, Frilling A et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab. 1996;81(5):1780-1783.

26. Romei C, Mariotti S, Fugazzola L et al. ItaMEN network, MEN 2: results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010;163(2):301-308.

27. Schilling T, Burck J, Sinn H-P et al. Prognostic value of codon (ATG3ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer (Pred. Oncol.). 2001;95:62-66.

28. Elisei R, Barbara Cosci B, Romei C et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682-687.

29. Marsh DJ, Learoyd DL, Andrew SD et al. Somatic mutations in the RET protooncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf). 1996;44:249-257.

30. Goutas N, Vlachodimitropoulos D, Bouka M et al. MBRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res. 2008;28:305-308.

31. Moura MM, Cavaco BM, Pinto AE et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 2009; 100(11):1777-1783.

32. Dockhorn-Dworniczak B, Caspari S, Schroder S et al. Demonstration of activated oncogenes of the ras family in human thyroid tumors using the polymerase chain reaction. Verh Dtsch Gas Pathol. 1990;74:415-418.

33. Wells SA, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial (ZETA). J Clin Oncol. 2012;30:134-141.